Medtronic plc — Form 10-Q Summary
Business context and reporting period
Medtronic reports results for its fiscal third quarter ended January 29, 2021, and the nine months then ended. The filing describes fiscal 2021; the quarter is not calendar 2020 Q3. The company develops and sells medical devices, therapies, and related services across cardiovascular, minimally invasive therapies, restorative therapies, and diabetes markets.
COVID-19 continued to affect procedure volumes, customer demand, supply chains, and product launches. Management said third-quarter results reflected recovery from the pandemic’s April lows, but the late-December and January resurgence slowed recovery in several businesses.
Financial results and liquidity
| Metric | Quarter ended Jan. 29, 2021 | Comparable prior quarter | Nine months ended Jan. 29, 2021 | Comparable prior period |
|---|---|---|---|---|
| Net sales | $7.775 billion | $7.717 billion | $21.929 billion | $22.916 billion |
| Operating profit | $1.277 billion | $1.639 billion | $2.879 billion | $4.475 billion |
| Net income attributable to Medtronic | $1.270 billion | $1.915 billion | $2.246 billion | $4.143 billion |
| Diluted GAAP EPS | $0.94 | $1.42 | $1.66 | $3.07 |
| Non-GAAP diluted EPS | $1.29 | $1.44 | $2.93 | $4.02 |
| Operating cash flow | Not separately stated for the quarter | Not separately stated for the quarter | $4.495 billion | $5.784 billion |
| Free cash flow | Not separately stated for the quarter | Not separately stated for the quarter | $3.517 billion | $4.907 billion |
Quarterly GAAP operating margin was approximately 16.4%, versus 21.2% a year earlier; nine-month operating margin was approximately 13.1%, versus 19.5%. GAAP earnings comparisons are affected by tax items and other adjustments; non-GAAP EPS also declined year over year.
At January 29, 2021, cash and cash equivalents were $5.077 billion and current investments were $9.562 billion, for total cash and current investments of $14.6 billion. Current debt was $3.821 billion and long-term debt was $26.502 billion. The company had no commercial paper outstanding and no borrowings under its $3.5 billion revolving credit facility. Management said liquidity was sufficient for foreseeable operating needs for at least 12 months.
Material changes versus the prior comparable periods
- Quarterly sales rose 1%, while nine-month sales fell 4%. Management estimates the extra fiscal selling week benefited nine-month sales by approximately $360 million to $390 million.
- Quarterly sales growth was led by Minimally Invasive Therapies, up 6%, including 27% growth in Respiratory, Gastrointestinal, and Renal, largely from COVID-related ventilator and respiratory demand. Cardiac and Vascular sales fell 4%. Nine-month sales declined across several procedure-dependent businesses.
- Nine-month operating cash flow decreased $1.289 billion, primarily reflecting lower customer collections and higher income-tax payments. Free cash flow decreased $1.390 billion.
- Total debt rose from $24.8 billion at April 24, 2020 to $30.3 billion, reflecting borrowing and debt issuance, redemption activity, and currency movements. The company issued approximately $7.2 billion of Euro-denominated notes and used proceeds in part to redeem debt.
Outlook, management commentary, risks, and unusual items
- No specific consolidated revenue or EPS guidance is provided in the supplied filing text. Management cautions that COVID-19’s duration and severity, procedure recovery, hospital capacity, staffing, and patient willingness to schedule procedures remain uncertain. Ventilator demand is expected to normalize in future quarters, though management expects it to remain above pre-pandemic levels.
- Management estimates Enterprise Excellence restructuring charges of $1.6 billion to $1.8 billion and expects $500 million to $700 million of gross annual savings by fiscal 2022. The new Simplification program is expected to generate annual savings of approximately $450 million to $475 million, with estimated charges of $400 million to $450 million; most charges for both programs are expected by the end of fiscal 2022.
- Unusual items include a $308 million debt-extinguishment loss in the nine-month period, $466 million of restructuring and associated costs, and a $130 million net benefit from certain tax adjustments. The comparable prior nine-month period included a $839 million net tax benefit, contributing to the large decline in reported GAAP earnings.
- Accrued litigation was approximately $0.5 billion. The company warns that ultimate costs could differ materially from estimates; some matters, including hernia mesh litigation, have no recorded damages expense because losses are not currently considered probable or reasonably estimable.
- Other stated risks include competitive launches and pricing pressure, regulatory approvals, product quality and recalls, foreign exchange exposure, supply interruptions, reimbursement changes, and tax disputes. The filing discusses a voluntary recall of the Valiant Navion Thoracic Stent Graft System and plans to restore production of the prior-generation product.
Important facts for investors to verify
- Whether procedure volumes and sales recover sustainably, particularly in Cardiac and Vascular and Restorative Therapies, and whether COVID-related respiratory demand normalizes as expected.
- How much of reported sales performance reflects the extra selling week, currency movements, and temporary demand or procedure effects.
- Progress against restructuring savings targets, the timing and cash cost of charges, and the impact on operating margins.
- Debt maturities and refinancing, including repayment of the €750 million floating-rate notes due March 2021 and the extended yen term loan.
- Developments in significant litigation and tax matters, including the Puerto Rico income-allocation case and environmental proceedings.